Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative breast cancer (TNBC) – <br />Results from GeparSixto<br /><br />Gunter von Minckwitz, Eric Hahnen, Peter A. Fasching, Jan Hauke, Andreas Schneeweiss, Christoph T. Salat, Mahdi Rezai, Jens U.

Blohmer, Dirk M. Zahm, Christian Jackisch, Bernd Gerber, Peter Klare, Sherko Kümmel, Holger Eidtmann, Stephan Paepke, Valentina Nekljudova, Sibylle Loibl, Michael Untch, Rita Schmutzler <br />for the <br />GBG/AGO-B study groups<br />

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Introduction

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 3

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 4

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Selected Objectives

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Key Eligibility Criteria

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR Rates (ypT0 ypN0) <br />

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 8

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Characteristics of patients with TNBC

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR Rates (%) in Patients with TNBC

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Slide 11

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR (ypT0 ypN0) <br />in all Patients with TNBC

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

pCR (ypT0/is ypN0) <br />in all Patients with TNBC

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Prediction of Carboplatin Effect on pCR

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Summary

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Conclusion

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Acknowledgements

Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting